-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PRadJTW/W5sU+h+aqUM1bScFPSnbHQaoI5Qz6qBmpYawuQtxh/XfX6Cx7N8s6KMZ SHcX+ciyS/zkWWjA5l9TSQ== 0000912057-00-008517.txt : 20000228 0000912057-00-008517.hdr.sgml : 20000228 ACCESSION NUMBER: 0000912057-00-008517 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20000225 GROUP MEMBERS: BIOTECHNOLOGY VALUE FUND L P GROUP MEMBERS: BIOTECHNOLOGY VENTURE PARTNERS, L.P. GROUP MEMBERS: BVF INC. GROUP MEMBERS: BVF PARTNERS L.P SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: PROTEIN POLYMER TECHNOLOGIES INC CENTRAL INDEX KEY: 0000858155 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 330311631 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-42404 FILM NUMBER: 553970 BUSINESS ADDRESS: STREET 1: 10655 SORRENTO VALLEY RD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195586064 MAIL ADDRESS: STREET 1: 10655 SORRENTO VALLEY ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY VALUE FUND L P CENTRAL INDEX KEY: 0000918923 STANDARD INDUSTRIAL CLASSIFICATION: INVESTMENT ADVICE [6282] IRS NUMBER: 363924731 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 227 W MONROE STREET, SUITE 4800 STREET 2: 227 W MONROE STREET, SUITE 4800 CITY: CHICAGO STATE: IL ZIP: 60606 MAIL ADDRESS: STREET 1: 227 W MONROE STREET, SUITE 4800 STREET 2: 227 W MONROE STREET, SUITE 4800 CITY: CHICAGO STATE: IL ZIP: 60606 SC 13D/A 1 SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ------------- SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) (Amendment No. _2_)(1) PROTEIN POLYMER TECHNOLOGIES, INC. ---------------------------------- (Name of Issuer) Common Stock ------------ (Title of Class of Securities) 74369 7 104 ----------- (CUSIP Number) Hope Flack BVF Partners L.P 227 West Monroe Street, Suite 4800 Chicago, Illinois 60606 (312) 263-7777 ----------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) February 17, 2000 ----------------- (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box / / NOTE: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. (Continued on following pages) (Pages 1 of 8 Pages) - ------------------ (1) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, SEE the NOTES). CUSIP NO. 74369 7 104 13D Page 2 of 8 Pages - ------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: BIOTECHNOLOGY VALUE FUND, L.P. I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY): - ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /X/ (b) / / - ------------------------------------------------------------------------------- 3 SEC USE ONLY - ------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE - ------------------------------------------------------------------------------- NUMBER 5 SOLE VOTING POWER OF 0 SHARES -------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER OWNED BY 272,000 EACH -------------------------------------------------- REPORTING 7 SOLE DISPOSITIVE POWER PERSON 0 WITH -------------------------------------------------- 8 SHARED DISPOSITIVE POWER 272,000 - ------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 272,000 - ------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* / / - ------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.0% - ------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON* PN - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! CUSIP NO. 74369 7 104 13D Page 3 of 8 Pages - ------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: BIOTECHNOLOGY VENTURE PARTNERS, L.P. I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY): - ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /X/ (b) / / - ------------------------------------------------------------------------------- 3 SEC USE ONLY - ------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE - ------------------------------------------------------------------------------- NUMBER 5 SOLE VOTING POWER OF 0 SHARES -------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER OWNED BY 240,000 EACH -------------------------------------------------- REPORTING 7 SOLE DISPOSITIVE POWER PERSON 0 WITH -------------------------------------------------- 8 SHARED DISPOSITIVE POWER 240,000 - ------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 240,000 - ------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* / / - ------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 1.8% - ------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON* PN - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! CUSIP NO. 74369 7 104 13D Page 4 of 8 Pages - ------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: BVF PARTNERS L.P. I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY): - ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /X/ (b) / / - ------------------------------------------------------------------------------- 3 SEC USE ONLY - ------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE - ------------------------------------------------------------------------------- NUMBER 5 SOLE VOTING POWER OF 0 SHARES -------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER OWNED BY 552,000 EACH -------------------------------------------------- REPORTING 7 SOLE DISPOSITIVE POWER PERSON 0 WITH -------------------------------------------------- 8 SHARED DISPOSITIVE POWER 552,000 - ------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 552,000 - ------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* / / - ------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 4.1% - ------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON* PN - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! CUSIP NO. 74369 7 104 13D Page 5 of 8 Pages - ------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: BVF INC. I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY): - ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /X/ (b) / / - ------------------------------------------------------------------------------- 3 SEC USE ONLY - ------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE - ------------------------------------------------------------------------------- NUMBER 5 SOLE VOTING POWER OF 0 SHARES -------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER OWNED BY 552,000 EACH -------------------------------------------------- REPORTING 7 SOLE DISPOSITIVE POWER PERSON 0 WITH -------------------------------------------------- 8 SHARED DISPOSITIVE POWER 552,000 - ------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 552,000 - ------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* / / - ------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 4.1% - ------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON* IA, CO - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! CUSIP NO. 74369 7 104 13D Page 6 of 8 Pages This Amendment No. 2 (the "Amendment") to the Statement on Schedule 13D, dated April 17, 1998, as amended first by Amendment No. 1, dated September 8, 1998 (as amended, the "Statement"), is being filed with the Securities and Exchange Commission on behalf of Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF"), Biotechnology Venture Partners, L.P., a Delaware limited partnership ("Venture"), BVF Partners L.P., a Delaware limited partnership ("Partners"), and BVF Inc., a Delaware corporation ("BVF Inc." and, together with BVF, Venture and Partners, the "Reporting Persons") with respect to the Common Stock, par value $0.01 per share (the "Stock"), of Protein Polymer Technologies Inc., a Delaware corporation ("PPT"). The principle office of PPT is located at 10655 Sorrento Valley Road, San Diego, CA, 92121. Item 3 is hereby amended to read in its entirety as follows: ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. Since December 17, 1999, the following are the only transactions undertaken by the Reporting Persons. Partners, in its capacity as general partner of BVF, has sold on behalf of such limited partnership 50,000 shares of the Stock for consideration of $78,512.38. In addition, Partners, in its capacity as investment manager with respect to certain managed accounts, has sold on behalf of such managed accounts 50,000 shares of the Stock for consideration of $78,512.38. Item 5 is hereby amended to read in its entirety as follows: ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. (a) BVF beneficially owns 272,000 shares of the Stock, Venture beneficially owns 240,000 shares of the Stock, Partners beneficially owns 552,000 shares of the Stock, and BVF Inc. beneficially owns 552,000 shares of the Stock, approximately 2.0%, 1.8%, 4.1% and 4.1%, respectively, of the aggregate number of shares outstanding as of November 1, 1999 (as reported in PPT's most recent quarterly statement on Form 10-Q). (b) BVF shares voting and dispositive power over the 272,000 shares of the Stock it beneficially owns with Partners. Venture shares voting and dispositive power over the 240,000 shares of the Stock it beneficially owns with Partners. Partners and BVF Inc. share voting and dispositive power over the 552,000 shares of the Stock they beneficially own with, in addition to BVF and Venture, the managed accounts on whose behalf Partners, as investment manager, purchased such shares. The managed accounts on whose behalf Partners owns shares of the Stock are Investment 10 L.L.C., an Illinois limited liability company ("ILL10") and Biotechnology Value Fund, Ltd., a Cayman Islands corporation ("BVF Ltd."). ILL10 and BVF Ltd. are collectively referred to herein as the "Accounts." The Accounts specialize in holding biotechnology stocks for investment purposes and the business address of each is BVF Partners L.P., 227 West Monroe Street, Suite 4800, Chicago, Illinois 60606. (c) Exhibit B attached hereto contains information as to all transactions in the Stock by the Reporting Persons during the past sixty days. All of the transactions were made for cash CUSIP NO. 74369 7 104 13D Page 7 of 8 Pages in open market, over-the-counter transactions. No other transactions in the Stock have been effected by the Reporting Persons during the past sixty days. (d) The Accounts are entitled to receive dividends and any sale proceeds with respect to the Stock in proportion to its respective ownership interest therein. Item 7 is hereby amended to read in its entirety as follows: ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. Exhibit A - Agreement Regarding Joint Filing Exhibit B - Transactions in the Stock by the Reporting Persons during the last 60 days. CUSIP NO. 74369 7 104 13D Page 8 of 8 Pages After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 24, 2000 BIOTECHNOLOGY VALUE FUND, L.P. By: BVF Partners L.P., its general partner By: BVF Inc., its general partner By: /s/ Mark N. Lampert ------------------------------- Mark N. Lampert President BIOTECHNOLOGY VENTURE PARTNERS, L.P. By: BVF Partners L.P., its general partner By: BVF Inc., its general partner By: /s/ Mark N. Lampert -------------------------------- Mark N. Lampert President BVF PARTNERS L.P. By: BVF Inc., its general partner By: /s/ Mark N. Lampert ----------------------------- Mark N. Lampert President BVF INC. By: /s/ Mark N. Lampert -------------------------- Mark N. Lampert President EX-99.A 2 EXHIBIT 99A EXHIBIT 99(a) AGREEMENT REGARDING JOINT FILING The undersigned, Biotechnology Value Fund, L.P., a Delaware limited partnership, Biotechnology Value Fund II, L.P., a Delaware limited partnership, BVF Partners L.P., a Delaware limited partnership, and BVF Inc., a Delaware corporation, hereby agree and acknowledge that the information required by the Amendment containing the information required by Schedule 13D, to which this Agreement is attached as an exhibit, is filed on behalf of each of them. The undersigned further agree that any further amendments or supplements thereto shall also be filed on behalf of each of them. Dated: February 24, 2000 BIOTECHNOLOGY VALUE FUND, L.P. By: BVF Partners L.P., its general partner By: BVF Inc., its general partner By: /s/ Mark N. Lampert ------------------------------- Mark N. Lampert President BIOTECHNOLOGY VENTURE PARTNERS, L.P. By: BVF Partners L.P., its general partner By: BVF Inc., its general partner By: /s/ Mark N. Lampert -------------------------------- Mark N. Lampert President BVF PARTNERS L.P. By: BVF Inc., its general partner By: /s/ Mark N. Lampert ----------------------------- Mark N. Lampert President BVF INC. By: /s/ Mark N. Lampert -------------------------- Mark N. Lampert President EX-99.B 3 EXHIBIT 99B EXHIBIT 99(b) TRANSACTIONS IN THE STOCK BY THE REPORTING PERSONS DURING THE PAST SIXTY DAYS
For the Account Price per Settlement Date By of Quantity Share Type of Trade Broker - --------------------------------------------------------------------------------------------- 2/17/99 Partners BVF 50,000 $1.5703 Sale HRZG - --------------------------------------------------------------------------------------------- 2/17/99 Partners BVF Ltd. 50,000 $1.5703 Sale HRZG - ---------------------------------------------------------------------------------------------
HRZG = Herzog, Hein & Geduld -----END PRIVACY-ENHANCED MESSAGE-----